Evidence map›Paper›PMID 37449600›Full record

ArticleNeural regeneration research2023

Potential role of

Yamunadevi Lakshmanan, Francisca Siu Yin Wong, Kwok-Fai So, Henry Ho-Lung Chan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neural regeneration research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Bioactive Components ofMolecules (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Yamunadevi LakshmananCentre for Eye and Vision Research (CEVR), 17W Hong Kong Science Park, Hong Kong Special Administrative Region, China.
Francisca Siu Yin WongCentre for Eye and Vision Research (CEVR), 17W Hong Kong Science Park, Hong Kong Special Administrative Region, China.
Kwok-Fai SoGuangdong-Hongkong-Macau (GHM) Institute of CNS Regeneration, Jinan University, Guangzhou, Guangdong Province; Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Henry Ho-Lung ChanCentre for Eye and Vision Research (CEVR), 17W Hong Kong Science Park; Laboratory of Experimental Optometry (Neuroscience), School of Optometry, The Hong Kong Polytechnic University; Research Centre for SHARP Vision (RCSV), The Hong Kong Polytechnic University; University Research Facilities in Behavioral and Systems Neuroscience (UBSN), The Hong Kong Polytechnic University, Hong Kong Special Administrative Region, China.
Hong Kong Polytechnic University · HKJinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the pharmacological benefits of herbal extracts have been revisited for their potential neuroprotective effects in glaucoma. The polysaccharides extracted from the fruits of Lycium barbarum L., or Lycium barbarum polysaccharides, exert their anti-aging effect through reducing oxidative stress, modulating the immune response, enhancing neuronal responses, and promoting cytoprotection. The therapeutic efficacy of Lycium barbarum polysaccharides in preserving retinal ganglion cells and their functions was demonstrated in a range of experimental models of optic neuropathies. These include the acute and chronic ocular hypertension models, the partial optic nerve transection model, and the ischemic-reperfusion injuries model. Based on these findings, Lycium barbarum polysaccharides appear to be a good candidate to be developed as a neuroprotective agent for treating multifactorial diseases. This review aims to present a comprehensive review on the latest preclinical evidence on the pre- and post-treatment benefits of Lycium barbarum polysaccharides in retinal ganglion cell neuroprotection. The possible mechanisms of Lycium barbarum polysaccharides mediating retinal ganglion cell neuroprotection will also be described. Moreover, the potential research gaps in the effective translation of Lycium barbarum polysaccharides treatment into clinical glaucoma management will be discussed.

Indexed as

animal modelcomplementary and alternative medicineglaucomaLycium barbarumneuroprotectionneuro-rescueocular hypertensionpolysaccharidepost-treatmentpre-treatmentretinal ganglion cell

Identifiers

PMID37449600
PMCPMC10358649
OpenAlexW4313004754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.